M.D., MPH, Executive Director, Head of Drug Safety and Pharmacovigilance/ Zogenix, Inc.
Dr. Agarwal is currently head of global clinical drug safety and pharmacovigilance at Zogenix. He was trained as a cardiologist and practiced medicine in the USA. He received Master of Public Health (MPH) from Harvard School of Public health with a concentration in the clinical research. He worked on the genetics of hypertension and drug-eluting coronary stent research at Harvard Medical school. Now more than a decade Dr. Agarwal is involved with clinical research in the pharmaceutical industry. In the past, he worked at GSK, Pfizer, and Gilead Sciences. He is an avid advocate of finding new methods to rapidly identify adverse drug reaction with the help of machine learning and artificial intelligence.
Presentation Title and Company Description
AI and Data Science Showcase: Machine learning and Adverse Drug Reaction
Zogenix is developing and commercializing therapies for central nervous system disorders that address specific clinical needs for people living with orphan diseases and other CNS disorders who need innovative treatment. Zogenix was founded in 2006 and has offices in California.